Clinical research involving human participants is governed by federal regulations that have bl'!en promulgated by the Department of Health and Human Services (DHHS) and the Food and Drug Administration (FDA). 8 In light of the proliferation of medical research, however, an increasing number of critics are voicing serious concerns about inadequate enforcement of the regulations· and unacceptable research risks. 9 In recent years, several subjects have died as a result of treatment received in clinical trials and several well-publicized lawsuits have been filed against researchers, research institutions, and institutional review boards (IRBs ).
10
The most prominent case is that of Jesse Gelsinger, an eighteen-year old man with a rare metabolic disease, who died . while undergoing experimental genetic therapr administered in a clinical study at the University of Pennsylvania.
1
In addition, a healthy research volunteer died as a res~lt of an experiment r_el~tin~ to asthma that was c?nd~cted at Johns Hopkins School of Medtcme. CHRON. HIGHER Eouc., Nov. 6, 2000 , available at htip:/lchronicle.comldailyl 2001 /ll/2000 Robert Steinbrook, Protecting Research Subjects -The Crisis at Johns Hopkins, 346 N. ENGL. J. MED. 716-720 (2002) . In the study, subjects were instructed to inhale a drug called hexamethonium that causes airways to constrict, and physicians observed the subject's airways as they took deep breaths. !d. at 717. 13 Robertson v. McGee, (filed Jan. 29, 2001 ). The plaintiffs seek damages arising from alleged failures to comply with the federal regulations that govern biomedical research. Id
Hutchinson Cancer Research Center in Seattle.
14 Intensifying concerns about both human subject welfare and potential liability are stimulating urgent calls for regulatory reforms.
Part I of this Article provides a brief historical overview of Twentieth Century research abuses and the development of regulatory oversight in the United States. Part II discusses informed consent, IRBs, and the regulations that govern them. Part III analyzes contemporary deficiencies in the regulatory system. Finally, Part IV offers recommendations for reform.
II. A HISTORICAL OVERVIEW OF RESEARCH ABUSES AND THE DEVELOPMENT OF RESEARCH REGULATIONS
During World War II, the Nazis conducted large-scale, experiments on concentration camp prisoners that were designed not . only to gather medical data, but also to torture and kill the subjects. In some camps, German doctors infected numerous healthy inmates with yellow fever, smallpox, ~bus, cholera, and diphtheria germs that caused hundreds of them to die. 5 In other camps Nazi physicians conducted experiments relating to high altitude, malaria, fret)zing, mustard fflas, bone transplantation, sea water, sterilization, and incendiary bombs. The full scope and ghastliness of the Nazi medical experimentation was revealed and documented during the Nuremberg Trials after World War II. 17 In the United States, medical research was conducted for many decades without any regulatory oversight. 18 Perhaps not surprisingly, in an environment devoid of regulation and monitoring, an alarming number of 14 Wright v. Fred Hutchinson Cancer Research Ctr, No. 01-2-008376 (Kitsap County Sup. Ct. filed Mar. 29, 2001 ). The complaint alleges that subjects were not fully informed of the study's risks, and that the investigators were unduly influenced by the allure of potential financial profits. The experiments were done without the subjects' knowledge or consent. 28 .
In 1972, news of the notorious Tuskegee syphilis study highlighted the problem of mistreatment of medical research subjects in the United States.
29
The Tuskegee study, whose participants were all AfricanAmerican men, was conducted from 1932 until the beginning of the 1970s and sought to analyze the natural progression of untreated syphilis. 30 The researchers, therefore, did not provide patients with penicillin, an antibiotic that is a fully effective cure for syphilis and was widely available as early 
B. IRBs
Research that is conducted, supported, or regulated by DHHS, the FDA, or another federal agency must be reviewed by an IRB. 40 An IRB is a committee designated by an institution to provide initial approval and periodic monitoring for biomedical research studies. 41 The IRB's primary purpose is to protect the rights and welfare of human subjects. 42 The IRB reviews a document known as the "protocol" for each proposed clinical trial, which describes the objectives of the research, its procedures, eligibility requirements for participants, the number of subjects to be tested, and other details. 43 The material submitted to the IRB also includes a document known as the "informed consent" form, which is given to all potential enrollees in order to provide them with a detailed explanation of the clinical trial and an opportunity to agree to participation in the study.
44
Phase H trials are designed to determine the effectiveness of the therapy. /d. The treatment is administered to patients suffering from the condition for which the therapy is intended. The trial often involves I 00 to 300 people and lasts about two years. 
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After the IRB approves the informed consent form, all those who wish to become human subjects must sign a copy of the document, affirming the voluntariness oftheir choice.
45
The structure and duties of IRBs are governed by the DHHS and FDA regulations.
46 Each IRB must be composed of at least five members with diverse cultural and ethnic backgrounds, and both men and women should be included. 47 At least one member of the IRB should be a person whose principal concerns are in the scientific realm, and one individual's expertise should be nonscientific (e.g. a lawyer or minister). 48 Furthermore, to enhance its objectivity, each IRB must include at least one member who is not otherwise affiliated with the research facility and who has no immediate family members affiliated with the entity. 49 According to DHHS's Office for Protection from Research Risks (OPRR), now renamed the Office for Human Research Protection (OHRP), eighty-six percent of IRB members in 1995 were affiliated with academic research institutions as full-time faculty (56%), clinical and research staff (18%), and administrators (6%).
50
Academic institutions do not compensate IRB members for their work, and thus these individuals must volunteer their time without receiving payment or relief from other job duties. 5 1 Unless an expedited review is conducted, research protocols must be reviewed at IRB meetings at which a majority of members are present, including a member whose expertise is nonscientific.
52
Decisions concerning approval of each study are made by majority vote.
53
The IRB may approve, disapprove, or require modifications to the proposed research activities.
54
Investigators must be given written notification of the IRB's decisions, and IRBs are required to monitor the clinical trials they approve at intervals of at least once a year, or more Before approving a clinical trial, the IRB must ensure that· specific criteria are met. These include: (1) risks to participants are minimized; (2) risks to subjects are reasonable in light of anticipated benefits; and (3) selection of participants is equitable, and the protocol is sensitive to the particularized problems of research involving vitlnerable populations, such as children, prisoners, pregnant women, mentaHr disabled individuals, or economically or educationally deprived persons. 5
C. Informed Consent
The contents of informed consent forms are also govffrned by the federal regulations. The informed consent document must be written in language that is accessible to subjects.
58 Informed consent may not include language that waives any of the subject's rights or releases the institution or research personnel from liability for negligence.
59
The regulations further require that informed consent be obtained in writing from each enrollee, though they allow for certain exceptions.
60
The regulations specify certain data that must be featured on the informed consent document. This information includes a description of the research, an explanation of risks, benefits, and alternatives, a discussion of confidentiality, a list of contact people, and· a statement that participation is voluntary and may be discontinued at any time. [I]n seeking informed consent the following information shall be provided to each subject:
(I) A statement that the study involves research, an explanation of the purposes of the research and the expected duration of the subject's participation, a description of the procedures to be followed, and identification of any procedures which are experimental; (2) A description of any reasonably foreseeable risks or discomforts to the subject; A description of any benefits to the subject or to others which may reasonably be expected from the research; (3) A disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject; (4) A statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained;
79

D. Research Involving Only Existing Medical Records Or Tissue Samples
In some cases investigators conduct research that does not involve treatment of any human subject. Instead, the research entails the study of existing medical records or tissue sai11ples. 62 For example, researchers might want to determine whether patients who have . a particular type of cancer suffered certain symptoms before their diagnosis and might attempt to make that determination through an examination of their recorded medical histories. Investigators are not required to obtain informed consent from subjects for such research if the information is publicly available or if the researcher will record the data in a way that will make it impossible for subjects to be identified.
63
In addition, the regulations provide that an IRB may waive informed consent requirements if it finds "[t]hat the research presents no more than (5) For research involving more than minimal risk, an explanation as to whether any compensation and an explanation as to whether any medical treaJments are available if injury occurs and, if so, what they consist of or where further information may be obtained; (6) An explanation of whom to contact for answers to pertinent questions about the research and research subjects' rights, and whom to contact in the event of a researchrelated injury to the subject; and (7) A statement that participation is voluntary, refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled, ;md the subject may discontinue participation at any time without penalty or Joss of benefits to which the subject is otherwise entitled. (b) Additional elements of informed consent. When appropriate, one or more of the following elements of information shall also be provided to each subject: (I) A statement that the particular treatment or procedure may involve risks to the subject (or to the embryo or fews, if the subject is or may become pregnant) which are currently unforeseeable; (2) Anticipated circumstances under which the subject's participation may be terminated by the investigator without regard to the subject's consent; (3) Any additional costs to the subject that may result from participation in the research; (4) The consequences of a subject's decision to withdraw from the research and procedures for orderly termination of participation by the subject; (5) A statement that significant new finding developed during the course of the research which may relate to the subject's willingness to continue participation will be provided to the subject; and (6) The approximate number of subjects involved in the study. The OIG stated that the enormous workloads of many IRBs currently prevent them from adequately performing their review functions. A follow-up report issued by the Office of Inspector General in April of 2000 concluded that in the intervening two years, only minimal progress had been made to diminish the workload pressures of IRBs. 67 The number of initial reviews conducted by IRBs increased by an average of forty-two percent from 1993 to 1998, and some IRBs review up to 2,000 protocols per year.
68
Some IRBs also receive 200 or more reports of adverse events each month concerning the clinical trials they oversee. 69 An external review conducted at Johns Hopkins University after the death of a healthy human subject revealed that until June of 2001 a single IRB, meeting every two weeks, was responsible for the approval of 800 new protocols and the annual reviews they generated.
70
The reviewers emphatically stated:
" Alan Milstein, an attorney who has filed several lawsuits against physician investigators on behalf of clinical trial participants, has publiciy criticized IRBs as sharing the blame for alleged injuries to human subjects. In one article he stated that "[I]n our major institutions, where you've got Nobel scientists and Nobel doctors and well-regarded professors, the IRBs more or less simply rubber-stamp whatever protocol one of these men put before them." Foubister, supra note 14, at I.
80
See 1998 Hearing, supra note 9.
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Human Radiation Experiments found, after interviewing actual subjects that few realized they were involved in research, and many had little understanding of the informed consent forms they had signed.
81
Commonly; the problem is confusion about the differences between research and clinical treatment. 82 While some research subjects are healthy volunteers who would not otherwise seek medical treatment, many are patients with particular illnesses who are recruited for cliniCal research by their treating physicians. These patients are vulnerable to a phenomenon known as the "therapeutic misconception. " 83 Because they are sick and are recruited for enrollment by their doctors, they become convinced that their research participation will be of definite medical benefit to them. These patients are therefore resistant to explanations that treatments involved in clinical trials are unproven and experimental, no matter how clearly and explicitly these explanations are given.
Numerous studies have focused on the issue of informed consent and have revealed very troubling evidence concerning the ability of research subjects toprovide valid consent.
84
In a labor-induction study with fiftytwo participants, thirty-nine percent of the women were found to be unaware that they were participating in a research study although all had 81 See 1998 Hearing, supra note 9. 
!d.
Most people have been socialized to believe that physicians (at least ethical ones) always provide personal care. It may therefore be very difficult, perhaps nearly impossible, to persuade subjects that this encounter is different, particularly if the researcher is also the treating physician, who has previously satisfied the subject's ·expectations of personal care. Further, insofar as much clinical research involves persons who are acutely ill and in some distress, the well-known tendency of patients to regress and entrust their well-being to an authority figure would undercut any effort to dispel the therapeutic misconception. Even those who realized they were research subjects often misunderstood essential aspects of the study and their role in it. 86 Several investigators asked fifty cancer patients to review a hypothetical consent form for participation in a placebo-controlled clinical trial.
87
Subjects were asked to interpret four different statements in the consent form.
88
Depending on the statement, the subjects provided incorrect answers twenty-six to fifty-four percent of the time.
89
In another survey, forty-seven percent of responding researchers indicated that they thought few of their subjects, enrolled in multinational studies in the 1980s, knew they wete participating in controlled experiments, even though they had given written consent. 90 In two additional studies, over three quarters of physicians who were questioned believed that subjects rarely understood all the data given to them.
91
The difficulty of obtaining informed consent is exacerbated by the fact that informed consent documents are generally written in language that is technical and sophisticated and consequently inappropriate for the intended audience. Sci. 37, 43 (1978) . Gray states that the women's misunderstanding is attributable to several factors "including the generally low educational levels of the unaware subjects, the investigator's delegation to subordinates of the task of obtaining consent, seeking consent in the labor room, and providing little oral explanation -sign this and we can get started." Id. 3 HEALTH L. REv. 37 (1994) . A study of29 subjects from two clinical trials at the University of Alberta Hospitals revealed that 14 of them were unable to describe acclirately the type of research study in which they were enrolled and 17 could not list any risks associated with participation in the trial although risks had been explicitly explained to them. 248 JAMA 344, 346 (1982) (noting that "most of the consent forms are written in language that requires reading ability at the college level for comprehension of the investigator's purpose," and that only 27% of VA patients surveyed "had more than a high school education."). 93 PEDIATRICS 460, 461-62 (1994) were cited was the failure to obtain adequate informed consent from subjects.
BRADFORD H. GRAY, HUMAN SUBJECTS IN MEDICAL EXPERJMENTATION 103 (1975); See also Angela Estey et al., Are Research Subjects Able to Retain the Information They Are Given During the Consent Process?,
B. Informed Consent Is Particularly Difficult To Obtain From Gravely Ill Patients
Genuine informed consent is particularly difficult to obtain when the patients at issue suffer from life-threatening diseases.
99
The decisionmaking capacity of gravely ill patients is often compromised by the emotional trauma of their illnesses or by various social and familial pressures. Consequently, those who have the most to gain or lose from receiving experimental treatment are also those who are least able to provide meaningful informed consent.
Illness can be viewed as an "ontological assault" that undermines the patient's identity by "attacking the fundamental unity of mind and body." 100 A patient suffering from multiple sclerosis described the experience of disease in these words:
The most deeply held assumption of daily life is the assumption that I, personally, will continue to be alive and it is in light of this assumption that one engages in daily activities. The onset of illness, however, brings one concretely face-to-face with personal vulnerability .... Thus, the person who is ill . . . is unable readily to fit illness into the typified schema used to organize and interpret experience .... One finds oneself preoccupied with the demands of the here and now, confined to the present moment, unable effectively to project into the future.
101
Commentators have noted that serious sickness creates in patients a strong desire to be cared for and to be free of the responsibility and stress of decision-making, as though they were once again children. 102 Many scholars have noted that the thought processes of those suffering from prolonged or serious illnesses are often impaired and have urged that rese~ch f:rotoc~ls involving such patients be subject to h~ightened IRB scrutmy. illness increases, the ability of potential subjects to remember information relevant to their research participation decreases. 104 Seriously ill patients may experience depression, extreme anxiety, rage, denial, or desperation to find a cure, all of which may cloud their judgment and hamper their ability to evaluate the benefits and risks of a clinical trial. 105 therapies, or for which there are no standard therapies, should be considered vulnerable particularly when they are willing to take ahy risk for even a remote possibility of relief."); DeRenzo et al., supra note 83, at 69, 78 ("(T]he majority of studies conclude that seriously ill research subjects have difficulties in many facets of providing ethically valid consent," and "Serious disease produces desperation .... ETHICS 232, 233 (1996) (noting that patients dealing with illness may experience a reduction in their autonomy due to a variety of factors related to the physiologic and psychological impact of illness). See also Cassileth, supra note 92, at 898 (noting that "(b]edridden patients gave significantly fewer correct responses to each item on the recall test [concerning chemotherapy, radiation therapy, or surgery, to which they had consented the previous day] than did ambulatory patients").
105
Addicott, supra note 103, at 502-03; Hewlett, supra note 103, at 233.
It is clear that many IRBs inadequately perform their oversight functions. Their deficient performance, however, does not stem from deliberate misconduct or indifference towards the welfare of human subjects, but rather, from inadequate resources, unmanageable workloads, and, in some cases, insufficient expertise.
106 Alleviating these problems is essential to enhancing protection for clinical trial participants.
An effective means of improving the functioning of IRBs would be the addition of more full-time, paid, professionals to their staffs. The size of the professional staff would vary in accordance with the workloads of the IRBs. The professional staff members should be charged with the review of all protocols that are submitted for initial approval, amendment, and continuing review to the IRB. One or two members of the IRB with relevant medical expertise should also read each protocol and provide comments to the staff.
107
The professional staff should then provide written reports to the full IRB membership, summarizing the protocol and their recommendations. The IRB volunteers would be responsible for reading the reports, asking follow-up questions, and voting on whether to approve the protocol.
Under this system, each IRB member will not be required to read every page of every protocol, many of which are quite voluminous, and therefore IRB duties will become less burdensome. The system will also expedite the review process so that investigators will not have to wait several months for approval of their submitted proposals. Finally, professional staffs would assure that each protocol actually receives a thorough and systematic initial review and continued monitoring, which many commentators have suggested does not always occur when these tasks are left exclusively in the hands of well-meaning, but overworked volunteers.
108
Additional funding would obviously be needed to support the hiring of adequate professional staffs. To obtain the necessary economic support, IRBs could charge commercial research sponsors fot review of their protocols. Similarly, if the research is sponsored by a governmental entity, the sponsor could be required to add a fixed sum or a small percentage to 106 See Malinowski, supra note 7, at 63; Fleetwood, supra note 84, at 111.
107
Thus, a protocol relating to cancer treatment would be reviewed by professional staff members and .by one or more oncologists, and a protocol relating to therapy for heart disease would be reviewed by one or more cardiologists in addition to the professional staff. 
B. Informed Consent Procedures
Professor Jay. Katz of Yale Law School has warned that obtaining true informed consent is an "inordinately difficult task."
110 He suggests that researchers must disclose to study participants at least the following data:
(1) that the subjects are not only patients and, to the extent to which they are patients, that their therapeutic interests, even if not incidental, will be subordinated to scientific interests; (2) that it is problematic and indeterminate whether their welfare will be better served by placing their medical fate in the hands of a physician rather than an investigator; (3) that in opting for the care of a physician they may be better or worse off and for such and such reasons; ( 4) that clinical research will allow doctors to penetrate the mysteries of medicine's uncertainties about which treatments are best, dangerous, or ineffective; (5) that clinical research may possibly be in the patient's immediate best interest, perhaps promise benefits in the future, or provide no benefit, particularly if the patient is assigned to a control (placebo) arm of a study; (6) that research is governed by a research protocol and a research question and, therefore, his or her interests and needs will yield to the claims of science; and (7) that physicianinvestigators will respect whatever decision the subject ultimately makes.
111
To these I would add a few other suggestions. Much of the general infonnation discussed by Professor Katz should be included in a video shown at the beginning of the informed consent process. The video should clearly explain the difference between research and therapy and describe to subjects their obligation to provide meaningful consent. In this television age, people often find audio-visual aids to be an accessible and effective communication tool that is an essential supplement to written materials and verbal presentations. You Need to Know," which was intended to assist asymptomatic men over 50 in deciding whether to undergo prostate-specific antigen (PSA) tests.
112
The informed consent process should also rndude a . thorough discussion between the potential subject and the investigator or a research nurse, in which all the details of the trial are verbally explained.
113
Potential participants should then be quizzed to ascertain that they fully understand the information they have received and to determine whether they are able to articulate answers to specific questions. 114 The inform~d consent process should continue until the investigator is satisfied that the potential subject understands all necessary information. 115 Those who fail to demonstrate a satisfactory level of comprehension after the· investigator or a nurse has invested a reasonable amount of time and effort in the informed consent process should not be enrolled as human subjects.
116
To facilitate reading comprehension, informed consent documents should be written in simple lan~uage that can be understood by people with an eighth grade reading level. 
113
See Riecken & Ravich, supra note 93. The article discusses a survey of 188 male veteran patients who were human subjects in research projects in four VA hospitals. Thirty seven principal investigators were also surveyed. Of investigators who were personally . responsible for explaining the study to patients, approximately half reported that they spent less than 15 minutes obtaining informed consent from patients, and a third stated that they spent between 15 and 30 minutes. Riecken & Ravich, supra note 93, at 345. Twenty-eight percent of research participants did not realize that they were enrolled in a clinical trial, and they were concentrated in the studies in which the investigators invested the shortest periods of time in the consent process. Riecken & Ravich, supra note 93, at 345. Only one investigator had no unaware participants. He had given e.ach potential subject a short examination after providing an explanation of the study. If the patient did not pass, the trial was described again. Riecken & Ravich, supra note 93, at 347.
.
See Katz, supra note 92, at 36-37.
115
See Katz, supra note 92, at 36.
116
See Riecken & Ravich, supra note at 93.
117
Grossman., supra note 94, at 2212. The authors found that the typical consent form that describes a clinical oncology protocol is "too complex to be read by most patients and their families." The average person reads at approximately an eighth grade reading level, and the mean grade level required for comprehension of the forms that were studied was between 11.1 and 14.1, depending on the index used. See id.
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C. Storage Of Blood And Tissue Samples For Future Genetic Testing
Many clinical trials include blood tests or tissue biopsies. Once testing has been completed for purposes of the study, investigators often wish to store the blood or tissue samples for purposes of future genetic testing.
119
It is difficult to obtain meaningful informed consent for unknown future studies because researchers cannot accurately describe the research that will be conducted or the data that will be sought.
In addition, genetic testing raises important concerns about privacy and potential discrimination. 120 If confidentiality is not properly maintained and genetic data about an individual is disclosed to third parties, such as employers and insurers, theindividual might suffer discrimination.
121 For example, genetic testing might reveal that a person is susceptible to a particular cancer, leading employers who obtain these test results to decline to hire her and insurers to deny her coverage because of anticipated costs that will be generated by her likely poor health status in the future. 122 Consequently, it is important that careful efforts be made to obtain informed consent for the storage of blood and tissue samples for purposes of future genetic testing.
123 Consent for tissue storage should be separate from consent for the underlying clinical trial, and thus, the subject should receive two consent documents and be required to provide two consent signatures for studies that contemplate future genetic testing. Subjects must be alerted to the fact that the issue of tissue storage is different from the issue of participation in the underlying trial and that it requires a separate decision-making process.
The consent form should address how confidentiality will be safeguarded and inform subjects about whether their samples will be deidentified. It should also disclose to participants that they will not personally benefit from future genetic testing in that researchers will not contact subjects or their doctors to provide test results. Furthermore, subjects should be informed that the research sponsor might profit from future research if it develops a new drug or therapy that is successfully marketed but that the individuals whose samples were utilized will not receive a share of the sponsor's earnings.
Finally, the consent form should provide subjects with choices as to the type of research to be conducted using their samples. For example, participants in a clinical trial relating to preast cancer who agree to storage of their samples could be asked to select from among the following: 1) I agree to have my sample used for future genetic testing related to breast cancer; 2) I agree to have my sample used for future genetic testing related to diseases other than breast cancer; and 3) I agree to have my sample stored but wish the investigator to contact me for permission before any testing is conducted in the future. If subjects read, think about, and respond to specific questions, investigators can be reassured that participants have understood the choices they were required to make and have provided meaningful consent.
VI. CONCLUSION
Enhancement of protections for human subjects will undoubtedly impose added costs for clinical research. Increasing 1he number of IRB professionals will require funcling by private and. governinental research sponsors.
124
A conscientious effort to obtain meaningful consent may delay recruitment of subjects and completion of research.
125
A valid informed consent process mar, require several hours or even repeated conversations over a few days~ 26 Furthermore, if patients fully understand all components and risks of a protocol, they may more often refuse to enroll, making some studies difficult or, in rare cases, impossible to conduct.
127 These negative consequences, however, are outweighed by the advantages of enhancing the integrity of biomedical research, bolstering human subject protection, and reducing the likelihood of liability associated with clinical studies. Oct. 3, 1999 , at Al (discussing the difficulties faced by some investigators who wish to recruit patients to participate in clinical trials involving treatments for serious illnesses such as cancer, heart failure, and Parkinson's disease). /d.
